Year: 2021

10
November 2021
Enterome to present significant progress with its OncoMimics™ pipeline at Jefferies London Healthcare Conference
Read more
04
November 2021
Significant Progress with OncoMimics™ and EndoMimics™ pipelines of transformational medicines for cancer and immune diseases
Read more
04
October 2021
Enterome to attend upcoming conferences
Read more
16
September 2021
Enterome highlights Microbiome publication describing sibofimloc’s novel mechanism of action for the treatment of Crohn’s disease
Read more
12
July 2021
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma
Read more
01
July 2021
Enterome to present at upcoming investor conferences
Read more
16
June 2021
Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics
Read more
07
April 2021
Enterome to present at upcoming conferences
Read more
24
March 2021
Enterome receives FDA IND clearance for EO2463, an ‘OncoMimic’ based immunotherapy targeting liquid tumors
Read more

Enterome France

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex